Bristol Myers Squibb (CELG-RI) Cash from Operations (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Cash from Operations of 3393000000.0 for Q2 2026, down 13.38% year-over-year from 3917000000.0 in Q2 2025, and up 207.34% quarter-over-quarter from 1104000000.0 in Q1 2026.
Bristol Myers Squibb (CELG-RI) Cash from Operations (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Cash from Operations for 18 consecutive years, with 3393000000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 13.38% year-over-year to 3393000000.0; the TTM figure through Jun 2026 stood at 12782000000.0 (down 19.62% YoY), while the FY2025 annual figure was 14156000000.0, down 6.81% from the prior year.
- Cash from Operations improved to 3393000000.0 in Q2 2026 per CELG-RI's latest filing, from 1104000000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 6311000000.0 in Q3 2025 and bottomed at 1104000000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 3376055555.56 across 5 years, with a median of 3349500000.0 in 2022.
- On a YoY basis, Cash from Operations climbed as much as 68.4% in 2025 and fell as far as 55.53% in 2025.
- Bristol Myers Squibb's Cash from Operations stood at 3306000000.0 in 2022, then grew by 28.61% to 4252000000.0 in 2023, then advanced by 4.4% to 4439000000.0 in 2024, then sank by 55.53% to 1974000000.0 in 2025, then surged by 71.88% to 3393000000.0 in 2026.
- Business Quant data shows CELG-RI's Cash from Operations at 3393000000.0 in Q2 2026, 1104000000.0 in Q1 2026, and 1974000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 3.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.39 Bn |
| Jun 30, 2026 | 3.39 Bn |
| Mar 31, 2026 | 1.10 Bn |
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 1.97 Bn |
| Dec 31, 2025 | 1.97 Bn |
| Sep 30, 2025 | 6.31 Bn |
| Sep 30, 2025 | 6.31 Bn |
| Jun 30, 2025 | 3.92 Bn |
| Jun 30, 2025 | 3.92 Bn |
| Mar 31, 2025 | 1.95 Bn |
| Mar 31, 2025 | 1.95 Bn |
| Dec 31, 2024 | 4.44 Bn |
| Dec 31, 2024 | 4.44 Bn |
| Sep 30, 2024 | 5.59 Bn |
| Sep 30, 2024 | 5.59 Bn |
| Jun 30, 2024 | 2.33 Bn |
| Jun 30, 2024 | 2.33 Bn |
| Mar 31, 2024 | 2.83 Bn |
| Mar 31, 2024 | 2.83 Bn |